Clinical Trials Logo

Brain Metastases, Adult clinical trials

View clinical trials related to Brain Metastases, Adult.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05095766 Active, not recruiting - Clinical trials for Brain Metastases, Adult

Comparaison Between MRI Alone or Combined With Positron Emission Tomography for Brain Metastasis Diagnosis

ITIRR
Start date: November 23, 2017
Phase:
Study type: Observational

During gamma scalpel treatment of brain tumors and metastases, a follow-up magnetic resonance imaging (MRI) scan is performed. The radiologist who reviews the MRI assesses whether there is an increase in signal at the tumor site. This increase potentially indicates that the treatment was not effective. However, in 25% of cases (one in four people), this signal enhancement is not due to ineffective treatment, but to inflammation (swelling/damage) and tissue death around the tumor. This is why when an increase in signal is detected, additional follow-up is essential. The standard additional follow-up has an accuracy of about 83%. This is an observational study on patients with brain metastatis comparing MRI alone or combined to PET-FET to improve accuracy of diagnosis of metastasis recurrence.

NCT ID: NCT05087095 Active, not recruiting - Clinical trials for Brain Metastases, Adult

Managing Distress in Malignant Brain Cancer

Start date: March 23, 2022
Phase: N/A
Study type: Interventional

To identify potential adaptations of the managing cancer and living meaningfully (CALM) intervention that will be required for service members, Veterans, their beneficiaries, and civilian cancer metastasis to the brain (bMET) populations.

NCT ID: NCT03561896 Active, not recruiting - Clinical trials for Brain Metastases, Adult

Hypofractionated Brain Radiationcavity

Start date: January 2015
Phase: N/A
Study type: Interventional

Stereotactic radiosurgery or hypofractionated radiotherapy of the resection cavity after metastasectomy in cancer patients with brain metastases

NCT ID: NCT02978404 Active, not recruiting - Melanoma Clinical Trials

Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases

Start date: June 2, 2017
Phase: Phase 2
Study type: Interventional

Stereotactic radiosurgery (SRS) is increasingly administered as the sole treatment of brain metastases, in order to spare acute and long term side effects associated with whole brain radiotherapy. Local control of SRS treated lesions is good, but patients tend to develop additional brain metastases subsequently. Nivolumab is a modulator of the immune system. Treatment with Nivolumab is associated with an increase in local control and survival in patients with non-small cell lung cancer and clear cell renal cell carcinoma. In the presence of Nivolumab, treatment of brain metastases with SRS may trigger an immune reaction against cancer. Therefore, the combination of SRS with Nivolumab may reduce the development of new brain metastases and improve patient survival. The purpose of this study is to assess the effect of combining Nivolumab and SRS in controlling cancer progression. SRS will be administered to patients while they are receiving Nivolumab.